Alnylam Pharmaceuticals Inc

Find Ratings Reports
ALNY : NASDAQ : Health Care
$39.08 up 0.57 | 1.48%
Today's Range: 38.06 - 39.74
Avg. Daily Volume: 1416700.0
01/19/17 - 4:00 PM ET

Financial Analysis


ALNYLAM PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALNYLAM PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 8.91 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has decreased by 23.20% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)13.656.32
EBITDA ($mil)-103.18-73.06
EBIT ($mil)-106.68-78.33
Net Income ($mil)-104.07-76.79


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)713.141016.21
Total Assets ($mil)1312.911436.14
Total Debt ($mil)150.00.0
Equity ($mil)1014.971321.6


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin-755.81-1155.28
EBITDA Margin-755.81-1155.28
Operating Margin-781.45-1238.61
Sales Turnover0.030.04
Return on Assets-29.54-15.37
Return on Equity-38.21-16.7
Debt Q3 FY16 Q3 FY15
Current Ratio9.1418.24
Debt/Capital0.130.0
Interest Expense0.30.0
Interest Coverage-355.590.0


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)85.7784.71
Div / share0.00.0
EPS-1.21-0.91
Book value / share11.8315.6
Institutional Own % n/a n/a
Avg Daily Volume1444336.01097178.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 3.54 indicates a premium versus the S&P 500 average of 2.84 and a significant discount versus the industry average of 11.43. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ALNYLAM PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ALNY NM Peers 34.33   ALNY NM Peers 27.22

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

ALNY's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ALNY's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ALNY NM Peers 24.82   ALNY NA Peers 0.41

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

ALNY's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ALNY 3.54 Peers 11.43   ALNY -70.67 Peers 3.61

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ALNY is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, ALNY is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ALNY 96.31 Peers 136.62   ALNY -35.29 Peers 532.92

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ALNY is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ALNY significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades